Nivolumab companion diagnostic - Biodesix
Alternative Names: BDX 008Latest Information Update: 28 Nov 2020
At a glance
- Originator Biodesix
- Class Diagnostic agents; Protein diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer(Diagnosis) in USA
- 28 Dec 2018 No recent reports of development identified for clinical-Phase-Unknown development in Malignant-melanoma(Diagnosis) in USA
- 25 Oct 2017 Clinical trials in Non-small cell lung cancer (Diagnosis) in USA (unspecified route) before October 2017